Provigil and Sildenafil Interaction: What Prescribers and Patients Should Know

How Modafinil Affects Sildenafil Metabolism

Modafinil is a moderate inducer of CYP3A4 at steady-state concentrations achieved with daily dosing of 200 to 400 mg. Sildenafil depends on CYP3A4 for approximately 75 to 80% of its hepatic clearance, with CYP2C9 handling the remainder [2]. When modafinil upregulates CYP3A4 enzyme expression, the rate at which sildenafil is converted to its primary metabolite (N-desmethylsildenafil) increases.

The CYP3A4 Induction Pathway

The Provigil FDA label explicitly warns that modafinil can reduce plasma concentrations of CYP3A4 substrates, including cyclosporine, steroidal contraceptives, and midazolam [1]. Sildenafil is not named individually in the Provigil label, but it is a well-characterized CYP3A4 substrate per the Viagra prescribing information [3]. The induction effect takes 3 to 5 days of continuous modafinil dosing to reach clinical significance, because CYP enzyme protein turnover requires multiple half-lives.

Magnitude of the Effect

No dedicated modafinil-sildenafil pharmacokinetic trial has been published. The closest proxy comes from studies of other moderate CYP3A4 inducers. In a crossover study (N=12), the moderate CYP3A4 inducer bosentan reduced sildenafil AUC by 63% [4]. Modafinil's induction potency is considered weaker than bosentan's, so a 30 to 50% AUC reduction is the estimated range most pharmacologists apply to this pair. That reduction may or may not be clinically meaningful depending on the patient's baseline sildenafil dose and the condition being treated.

Why This Is Not a Two-Way Interaction

Sildenafil does not induce or inhibit CYP enzymes at therapeutic doses. It will not alter modafinil concentrations. The interaction is unidirectional: modafinil affects sildenafil, not the reverse [3].

Clinical Severity and Risk Classification

Major drug interaction databases classify the modafinil-sildenafil interaction as moderate severity. That classification means the combination is not contraindicated, but clinicians should adjust therapy or monitor more closely.

How Databases Rate This Pair

Lexicomp rates it as "C: Monitor therapy." Clinical Pharmacology assigns a moderate severity score. The Provigil label uses a general class warning for all CYP3A4 substrates rather than singling out specific drugs [1]. The FDA's Drug Development and Drug Interactions Table lists modafinil as a moderate CYP3A4 inducer and sildenafil as a sensitive CYP3A4 substrate [5].

When Severity Escalates

The interaction becomes more clinically relevant in three scenarios. First, patients taking sildenafil 25 mg for erectile dysfunction (the lowest available dose) have limited room for further exposure reduction. Second, patients using sildenafil 20 mg three times daily for pulmonary arterial hypertension (PAH) under the brand name Revatio depend on consistent plasma levels to maintain pulmonary vascular tone [6]. Third, patients who are also taking another CYP3A4 inducer (rifampin, carbamazepine, phenytoin) alongside modafinil face compounded induction that could reduce sildenafil levels below the therapeutic threshold entirely.

Dose Adjustment and Prescribing Strategies

The primary clinical concern is reduced sildenafil efficacy, not toxicity. Dose adjustment should aim to restore sildenafil exposure to the target range.

For Erectile Dysfunction (Sildenafil 25 to 100 mg PRN)

Patients who were stable on sildenafil 50 mg before starting modafinil may need to increase to 100 mg. Those already on 100 mg have reached the maximum recommended dose per the Viagra label and cannot titrate higher [3]. For these patients, consider separating dosing times so that sildenafil is taken during the trough of modafinil's induction effect (late evening, 10 to 12 hours after the morning modafinil dose), or discuss switching to a PDE5 inhibitor with less CYP3A4 dependence.

For Pulmonary Arterial Hypertension (Sildenafil 20 mg TID)

The Revatio label permits doses up to 20 mg three times daily. The SUPER-1 trial (N=278) established that 20 mg TID improved 6-minute walk distance by 45 meters over placebo [6]. If a PAH patient starts modafinil and shows clinical worsening (increased dyspnea, declining walk distance, rising NT-proBNP), the pulmonologist should reassess whether CYP3A4 induction is contributing. Dose escalation of sildenafil beyond the labeled 20 mg TID for PAH requires specialist judgment and hemodynamic monitoring.

Tadalafil as an Alternative

Tadalafil is also a CYP3A4 substrate, so modafinil will reduce tadalafil levels by a similar mechanism [7]. Switching from sildenafil to tadalafil does not solve the interaction. Avanafil is even more CYP3A4-dependent. Among PDE5 inhibitors, none fully escape this enzyme pathway.

Monitoring Recommendations

Monitoring this interaction is straightforward because the expected effect is reduced efficacy, not an adverse event.

What to Track for ED Patients

Ask about treatment response at the first follow-up after modafinil initiation (typically 2 to 4 weeks). The validated International Index of Erectile Function (IIEF-5) questionnaire provides a standardized measure. A drop of 4 or more points from baseline suggests clinically meaningful loss of response [8]. If the patient reports diminished sildenafil effect that correlates with modafinil start, titrate sildenafil up or adjust timing before adding a new medication.

What to Track for PAH Patients

For PAH patients, the 2022 ESC/ERS Pulmonary Hypertension Guidelines recommend serial assessment of functional class, 6-minute walk distance, BNP/NT-proBNP, and echocardiographic parameters [9]. Any decline in these markers within 4 to 8 weeks of adding modafinil warrants pharmacokinetic review. Therapeutic drug monitoring for sildenafil is available through specialty laboratories (target trough: 40 to 400 ng/mL for PAH), though it is not routine.

Timeline for Reassessment

The CYP3A4 induction effect of modafinil reaches steady state in approximately 5 days. Clinical impact on sildenafil efficacy may take 1 to 2 weeks to become noticeable for ED patients (since sildenafil is used on-demand) and days for PAH patients on scheduled dosing. If modafinil is discontinued, CYP3A4 activity returns to baseline within 7 to 14 days, and sildenafil doses should be reduced back to the original level to avoid excess exposure.

Modafinil's Broader CYP Interaction Profile

Understanding the full enzyme picture of modafinil helps predict interactions beyond sildenafil.

CYP3A4 Induction

This is the most clinically significant pathway. The Provigil label specifically mentions that ethinyl estradiol AUC decreased by 18% with concomitant modafinil 200 mg and by a greater magnitude at 400 mg [1]. Steroidal oral contraceptives require backup methods during and for one month after modafinil therapy. Cyclosporine blood levels dropped by 50% in a published case report involving a patient on modafinil 200 mg daily [10].

CYP2C19 Inhibition

Modafinil is also a moderate reversible inhibitor of CYP2C19 [1]. This means drugs metabolized by CYP2C19 (omeprazole, diazepam, phenytoin, propranolol) may have increased plasma levels during co-administration. This pathway does not affect sildenafil directly but matters for patients on multiple medications alongside the modafinil-sildenafil pair.

CYP2C9 Considerations

Sildenafil's minor metabolic pathway runs through CYP2C9. Modafinil does not meaningfully induce or inhibit CYP2C9 at standard doses, so this pathway does not compensate for or worsen the CYP3A4-mediated interaction [1].

Pharmacodynamic Overlap: Blood Pressure Effects

Beyond the pharmacokinetic interaction, both drugs have hemodynamic effects that deserve attention.

Sildenafil and Blood Pressure

Sildenafil produces a mean systolic blood pressure reduction of 8 to 10 mmHg at peak plasma concentration [3]. This is the mechanism behind its contraindication with nitrates, where additive vasodilation can cause life-threatening hypotension.

Modafinil and Blood Pressure

Modafinil may slightly increase blood pressure. In clinical trials, modafinil-treated patients showed mean increases of 1 to 3 mmHg in systolic and diastolic pressure compared to placebo [1]. This mild pressor effect could theoretically offset some of sildenafil's hypotensive action, though no study has measured the net hemodynamic effect of the combination.

Net Clinical Impact

The opposing hemodynamic effects likely cancel each other out in most patients. The 2015 American Urological Association guidelines on erectile dysfunction do not flag wakefulness-promoting agents as a blood pressure concern with PDE5 inhibitors [11]. Patients on antihypertensive therapy should have blood pressure checked within the first two weeks of starting either drug, regardless of the combination.

Special Populations

Hepatic Impairment

Both drugs are extensively hepatically metabolized. In patients with Child-Pugh B cirrhosis, sildenafil clearance drops by 47% [3], and the Provigil label recommends halving the modafinil dose in severe hepatic impairment [1]. The net direction of the interaction becomes harder to predict in liver disease because impaired baseline CYP3A4 activity may blunt the induction effect.

Older Adults

Adults over 65 have approximately 40% higher sildenafil AUC than younger adults due to reduced hepatic blood flow and CYP activity [3]. The modafinil induction effect might partially normalize sildenafil levels in this group, but dose adjustments should still be guided by clinical response rather than assumptions about offsetting pharmacokinetic changes.

CYP3A4 Poor Metabolizers

Genetic polymorphisms in CYP3A4 are uncommon compared to CYP2D6 or CYP2C19 variants. The CYP3A5*3 loss-of-function allele (present in 85 to 95% of Europeans) reduces total CYP3A activity modestly [12]. Patients with low baseline CYP3A activity may experience less induction from modafinil and therefore less sildenafil AUC reduction. Pharmacogenomic testing for CYP3A4/3A5 is not standard practice for this drug pair.

Patient Counseling Points

Patients prescribed both modafinil and sildenafil should receive clear, specific instructions.

Tell patients that modafinil may reduce how well sildenafil works. This is not dangerous. The concern is reduced effectiveness, not a harmful reaction. If sildenafil stops working as well after starting Provigil, the patient should contact their prescriber rather than doubling the dose independently. For ED patients, taking sildenafil in the evening (when morning modafinil levels have declined) may partially offset the interaction. Patients on sildenafil for PAH should never adjust their dose without specialist guidance.

Remind patients that stopping modafinil raises sildenafil levels back to normal within about two weeks. If they discontinue Provigil while on an increased sildenafil dose, they need to reduce sildenafil to avoid side effects such as headache, flushing, or visual disturbances.

The combination is not contraindicated with each other, but sildenafil remains absolutely contraindicated with nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite) regardless of modafinil use [3]. That safety rule does not change.